TABLE 6.
Pharmacokinetic parameters of rivaroxaban in rats after oral administration alone and combined multiple doses of almonertinib.
| Parameters (Unit) | Rivaroxaban (2 mg/kg, group 1) | Multiple-doses almonertinib with rivaroxaban (2 mg/kg, group 5) | Multiple-doses almonertinib with rivaroxaban (1 mg/kg, group 6) |
|---|---|---|---|
| AUC0-t (μg/L*h) | 763.89 ± 164.17 | 3,511.15 ± 783.84** | 2,216.88 ± 455.02** |
| AUC0-∞(μg/L*h) | 796.70 ± 168.72 | 3,536.15 ± 793.55** | 2,234.87 ± 464.38** |
| Cmax (μg/L) | 200.50 ± 37.99 | 862.00 ± 110.34** | 457.33 ± 101.03** |
| Tmax (h) | 0.92 ± 0.30 | 2.21 ± 0.95** | 2.08 ± 0.49** |
| t1/2z (h) | 6.84 ± 3.46 | 4.47 ± 0.80 | 4.30 ± 0.91 |
| CLz/F (L/h/kg) | 2.62 ± 0.62 | 0.60 ± 0.18** | 0.47 ± 0.12** |
| Vz/F (L/kg) | 26.35 ± 18.02 | 3.75 ± 0.72** | 2.83 ± 0.55** |
| MRT0-t (h) | 4.72 ± 0.57 | 3.94 ± 0.56* | 4.10 ± 0.41 |
| MRT0-∞ (h) | 6.09 ± 1.45 | 4.12 ± 0.60** | 4.30 ± 0.47** |
*p < 0.05, **p < 0.01, compared with 2 mg/kg rivaroxaban alone, demonstrating statistically significant difference. The main pharmacokinetic parameters are revealed as the mean ± standard deviation.